Cervix Carcinoma

Categories: Cancer diseases, Reproductive diseases

Aliases & Classifications for Cervix Carcinoma

MalaCards integrated aliases for Cervix Carcinoma:

Name: Cervix Carcinoma 12 15 71
Carcinoma of Cervix 12 29 6
Carcinoma of the Cervix Uteri 12
Carcinoma Cervix Uteri 12
Cancer of Cervix 12


External Ids:

Disease Ontology 12 DOID:2893
NCIt 49 C9039
SNOMED-CT 67 285432005
ICD10 32 C53 C53.9
UMLS 71 C0302592

Summaries for Cervix Carcinoma

Disease Ontology : 12 A cervical cancer that is located in the cervix uteri or located in the cervical area and that has material basis in abnormally proliferating cells derives from epithelial cells.

MalaCards based summary : Cervix Carcinoma, also known as carcinoma of cervix, is related to suppressor of tumorigenicity 3 and cervical cancer. An important gene associated with Cervix Carcinoma is FGFR3 (Fibroblast Growth Factor Receptor 3), and among its related pathways/superpathways are VEGF Signaling and Shigellosis. The drugs Vaccines and Fluorouracil have been mentioned in the context of this disorder. Affiliated tissues include cervix uteri, cervical area and cervix, and related phenotypes are immune system and neoplasm

Wikipedia : 74 Cervical cancer is a cancer arising from the cervix. It is due to the abnormal growth of cells that have... more...

Related Diseases for Cervix Carcinoma

Diseases related to Cervix Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 280)
# Related Disease Score Top Affiliating Genes
1 suppressor of tumorigenicity 3 33.3 TP53 FHIT
2 cervical cancer 32.6 TP53 STAT3 MIR218-1 MIR200A MIR141 HOXA11-AS
3 squamous cell carcinoma 30.8 TP53 STAT3 RHOA FHIT FGFR3
4 breast adenocarcinoma 30.8 TP53 RHOA H2AC18 ABCB1
5 endometriosis 30.3 TP53 MIR200A MIR199A1 MIR141
6 lymphoma, non-hodgkin, familial 30.2 TP53 STAT3 MIR199A1 H2AC18 CDKN3 ABCB1
7 bladder cancer 30.0 TP53 STAT3 MIR200A MIR199A1 MIR141 FHIT
8 breast cancer 28.9 TP53 STAT3 RHOA MIR200A MIR199A1 MIR141
9 adenoid basal carcinoma of the cervix uteri 12.7
10 high-grade neuroendocrine carcinoma of the cervix uteri 12.6
11 glassy cell carcinoma of the cervix uteri 12.6
12 papillary carcinoma of the cervix uteri 12.6
13 rare cancer of cervix uteri 12.3
14 cervix uteri carcinoma in situ 11.8
15 cervical adenocarcinoma 11.6
16 cervical squamous cell carcinoma 11.6
17 cervical clear cell adenocarcinoma 11.5
18 cervical endometrioid adenocarcinoma 11.5
19 malignant mixed epithelial and mesenchymal tumor of cervix uteri 11.3
20 primitive neuroectodermal tumor of the cervix uteri 11.3
21 cervical adenosquamous carcinoma 11.3
22 exocervical carcinoma 11.2
23 cervical adenoid cystic carcinoma 11.2
24 cervical adenoid basal carcinoma 11.2
25 cervical large cell neuroendocrine carcinoma 11.2
26 endocervical carcinoma 11.2
27 in situ carcinoma 10.7
28 uterine sarcoma 10.7 ABCC1 ABCB1
29 cheilitis 10.6 TP53 STAT3 FGFR3
30 colonic benign neoplasm 10.6 TP53 STAT3 H2AC18
31 temporal lobe neoplasm 10.6 ABCC1 ABCB1
32 esophagitis 10.6 TP53 STAT3 FHIT
33 esophagus adenocarcinoma 10.6 TP53 MIR362 MIR199A1
34 tonsil cancer 10.6 TP53 MIR199A1 H2AC18
35 vaginal disease 10.6 TP53 MIR218-1 H2AC18
36 lymphangioma 10.6 TP53 STAT3 H2AC18
37 melanoma in congenital melanocytic nevus 10.6 TP53 MIR199A1 H2AC18
38 soft tissue sarcoma 10.6 TP53 ABCB1
39 oropharynx cancer 10.6 TP53 MIR199A1 H2AC18
40 sexual disorder 10.6 RHOA MIR141 H2AC18
41 skeletal muscle cancer 10.6 TP53 MIR199A1 H2AC18
42 muscle cancer 10.6 TP53 MIR199A1 H2AC18
43 childhood leukemia 10.6 TP53 ABCC1 ABCB1
44 non-invasive bladder papillary urothelial neoplasm 10.5 TP53 FGFR3
45 intestinal benign neoplasm 10.5 TP53 STAT3 MIR199A1 H2AC18
46 cholangiocarcinoma 10.5 TP53 STAT3 MIR141 FHIT
47 pleural disease 10.5 TP53 MIR199A1 H2AC18
48 gastrointestinal system benign neoplasm 10.5 TP53 STAT3 MIR199A1 H2AC18
49 leukocyte disease 10.5 TP53 STAT3 MIR199A1 H2AC18
50 testicular disease 10.5 TP53 MIR199A1 H2AC18

Graphical network of the top 20 diseases related to Cervix Carcinoma:

Diseases related to Cervix Carcinoma

Symptoms & Phenotypes for Cervix Carcinoma

MGI Mouse Phenotypes related to Cervix Carcinoma:

# Description MGI Source Accession Score Top Affiliating Genes
1 immune system MP:0005387 9.7 ABCB1 ABCC1 BECN1 DUSP3 FGFR3 FHIT
2 neoplasm MP:0002006 9.17 BECN1 FGFR3 FHIT FOXM1 FOXO3 STAT3

Drugs & Therapeutics for Cervix Carcinoma

Drugs for Cervix Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 80)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1 Vaccines Phase 4
Fluorouracil Approved Phase 3 51-21-8 3385
Epirubicin Approved Phase 3 56420-45-2 41867
Cyclophosphamide Approved, Investigational Phase 3 50-18-0, 6055-19-2 2907
Topotecan Approved, Investigational Phase 3 123948-87-8, 119413-54-6 60700
Vinorelbine Approved, Investigational Phase 3 71486-22-1 60780 44424639
Imiquimod Approved, Investigational Phase 2, Phase 3 99011-02-6 57469
Metronidazole Approved Phase 2, Phase 3 443-48-1 4173
Nelfinavir Approved Phase 3 159989-64-7 64143
Ondansetron Approved Phase 3 99614-02-5 4595
Atezolizumab Approved, Investigational Phase 3 1380723-44-3
Bevacizumab Approved, Investigational Phase 3 216974-75-3
Cisplatin Approved Phase 3 15663-27-1 2767 441203 84093
Paclitaxel Approved, Vet_approved Phase 3 33069-62-4 36314
Carboplatin Approved Phase 3 41575-94-4 10339178 38904 498142
16 taxane Phase 3
17 Alkylating Agents Phase 3
18 Anti-Bacterial Agents Phase 3
19 Antibiotics, Antitubercular Phase 3
20 Antirheumatic Agents Phase 3
21 Adjuvants, Immunologic Phase 2, Phase 3
22 topoisomerase I inhibitors Phase 3
23 Immunoglobulins Phase 3
24 Antibodies Phase 3
25 Immunoglobulins, Intravenous Phase 3
26 Endothelial Growth Factors Phase 3
27 Mitogens Phase 3
28 Antibodies, Monoclonal Phase 3
29 Immunoglobulin G Phase 3
30 interferons Phase 2, Phase 3
31 Antiparasitic Agents Phase 2, Phase 3
32 Antiprotozoal Agents Phase 2, Phase 3
33 Anti-HIV Agents Phase 3
34 Antiviral Agents Phase 3
protease inhibitors Phase 3
36 HIV Protease Inhibitors Phase 3
37 Anti-Retroviral Agents Phase 3
38 Antineoplastic Agents, Immunological Phase 3
39 Angiogenesis Inhibitors Phase 3
40 Tubulin Modulators Phase 3
41 Antimitotic Agents Phase 3
42 Albumin-Bound Paclitaxel Phase 3
Cetuximab Approved Phase 2 205923-56-4 56842117 2333
Clotrimazole Approved, Vet_approved Phase 2 23593-75-1 2812
Miconazole Approved, Investigational, Vet_approved Phase 2 22916-47-8 4189
Sirolimus Approved, Investigational Phase 2 53123-88-9 5284616 6436030 46835353
Capecitabine Approved, Investigational Phase 2 154361-50-9 60953
Lenograstim Approved, Investigational Phase 2 135968-09-1
Sargramostim Approved, Investigational Phase 2 83869-56-1, 123774-72-1
Gemcitabine Approved Phase 2 95058-81-4 60750

Interventional clinical trials:

(show top 50) (show all 61)
# Name Status NCT ID Phase Drugs
1 Immune Response After Human Papillomavirus Vaccination in Patients With Autoimmune Disease Completed NCT00815282 Phase 4
2 Concurrent Chemoradiotherapy With Weekly Cisplatin Versus Concurrent Chemoradiotherapy With Weekly Cisplatin and Paclitaxel in Locally Advanced Carcinoma Cervix Unknown status NCT01593306 Phase 3 Paclitaxel, Cisplatin;Cisplatin
3 Assessment of the Impact of Preoperative Stress Reduction on Psychological, Physiological and Immunological Parameters in Women With Gynecological Malignancies - Prospective Randomized Controlled Trial Unknown status NCT00726635 Phase 3
4 High Dose Rate (HDR) Versus Low Dose Rate (LDR) Brachytherapy in Carcinoma Cervix Completed NCT00193830 Phase 3
5 Study of Two Fractions Versus Three Fractions High Dose Rate Brachytherapy in Locally Advanced Carcinoma of Uterine Cervix After Pelvic Concurrent Chemoradiotherapy - a Randomized Controlled Trial Completed NCT02765919 Phase 3
6 Phase 3 Randomized Comparison of Concurrent Gemcitabine, Cisplatin, and Radiation Followed by Adjuvant Gemcitabine and Cisplatin Versus Concurrent Cisplatin and Radiation in Cancer of the Cervix Stages IIB to IVA Completed NCT00191100 Phase 3 Gemcitabine;Cisplatin
7 A Prospective, Randomized, Open-label, Multicentric,phaseIII Clinical Trial Compared With PC and CEF100 Followed by Docetaxel as Adjuvant Chemotherapy Regimen for Chinese Primary Triple Negative Breast Cancer Patients Completed NCT01216111 Phase 3 Paclitaxel Cisplatin;fluorouracil epirubicin cyclophosphamide and docetaxel (FEC-T)
8 A Randomized Phase III Trial Of Paclitaxel Plus Cisplatin Versus Vinorelbine Plus Cisplatin Versus Gemcitabine Plus Cisplatin Versus Topotecan Plus Cisplatin In Stage IVB, Recurrent Or Persistent Carcinoma of the Cervix Completed NCT00064077 Phase 3 Cisplatin;Gemcitabine Hydrochloride;Paclitaxel;Topotecan Hydrochloride;Vinorelbine Tartrate
9 A Randomized Phase III Trial of Cisplatin Plus Paclitaxel With and Without NCI-Supplied Bevacizumab (NSC #704865) Versus the Non-platinum Doublet, Topotecan Plus Paclitaxel, With and Without NCI-Supplied Bevacizumab, in Stage IVB, Recurrent or Persistent Carcinoma of the Cervix Completed NCT00803062 Phase 3 Cisplatin;Paclitaxel;Topotecan Hydrochloride
10 Phase 3 Randomized Controlled Trial of Non-inferiority of Topical Imiquimod vs. LEEP for Women With Carcinoma In-situ of the Cervix Completed NCT02130323 Phase 2, Phase 3 Imiquimod
11 A Randomized Clinical Trial of Radiotherapy and Metronidazole Versus Radiotherapy Alone in Anaemic Patients With Advanced Cervical Cancer In Mulago Completed NCT01937650 Phase 2, Phase 3 Radiotherapy plus metronidazole
12 A Phase III Randomized Clinical Trial to Study the Radiosensitizing Effect of Nelfinavir in Locally Advanced Carcinoma of Uterine Cervix. Recruiting NCT03256916 Phase 3 Nelfinavir;Cisplatin
13 A Randomized Phase III Trial of Platinum Chemotherapy Plus Paclitaxel With Bevacizumab and Atezolizumab Versus Platinum Chemotherapy Plus Paclitaxel and Bevacizumab in Metastatic (Stage IVB), Persistent, or Recurrent Carcinoma of the Cervix Recruiting NCT03556839 Phase 3 Atezolizumab;Bevacizumab;Cisplatin;Paclitaxel
14 A Prospective Randomized Trial of Neoadjuvant Chemotherapy and Surgery Versus Concurrent Chemoradiation Therapy in Patients With Stage IB2-IIB Squamous Carcinoma of the Uterine Cervix Active, not recruiting NCT00193739 Phase 3 NACT;Inj.Cisplatin
15 Phase II, Prospective, Randomized, Non-comparative Study of Treatment With Induction Chemotherapy With Cisplatin and Gemcitabine Followed by Chemoradiation or Definitive Chemoradiation in Invasive Locally Advanced Carcinomas of Uterine Cervix. Unknown status NCT01973101 Phase 2 Cisplatin;Gemcitabine;cisplatin
16 Simultaneously Integrated Dose Escalation for Locally Advanced Cervical Cancer (SIDE, Advanced Squamous Cervical Cancer Trial) Unknown status NCT02879214 Phase 2
17 An Open Label Randomized Phase 2, Pilot Study to Investigate the Effectiveness of Palliative Chemotherapy in Stage IVB, Recurrent or Persistent Carcinoma Cervix Unknown status NCT02492503 Phase 1, Phase 2 Paclitaxel and carboplatin;Paclitaxel and carboplatin
18 Phase II Study Evaluating the Role of Tomotherapy- Based Intensity Modulated Radiotherapy and Brachytherapy in Postsurgery Recurrent Carcinoma Cervix Unknown status NCT01117402 Phase 2
19 A Phase II Evaluation Of Docetaxel (NSC #628503) In The Treatment Of Persistent Or Recurrent Squamous Cell Carcinoma Of The Cervix Completed NCT00041093 Phase 2 Docetaxel
21 A Phase II Evaluation of ABI-007 in the Treatment of Persistent or Recurrent Squamous or Nonsquamous Cell Carcinoma of the Cervix Completed NCT00309959 Phase 2 Paclitaxel Albumin-Stabilized Nanoparticle Formulation
22 A Phase II Evaluation of Cetuximab (Erbitux®, C225, NSC# 714692) in the Treatment of Persistent or Recurrent Squamous or Non-Squamous Cell Carcinoma of the Cervix Completed NCT00499031 Phase 2
23 A Phase II Study of Temsirolimus (NSC 683864), an mTOR Inhibitor, in Patients With Recurrent, Unresectable, Locally Advanced or Metastatic Carcinoma of the Cervix Completed NCT01026792 Phase 2 Temsirolimus
24 A Phase II Evaluation Of Capecitabine (NSC #712807) In The Treatment Of Persistent Or Recurrent Non-Squamous Cell Carcinoma Of The Cervix Completed NCT00039442 Phase 2 Capecitabine
25 A Phase II Evaluation of ABT-888 (NCI Supplied Agent: ABT-888, NSC #737664), Topotecan (NSC # 609699) and Filgrastim or Pegfilgrastim in the Treatment of Persistent or Recurrent Squamous or Non-squamous Cell Carcinoma of the Cervix Completed NCT01266447 Phase 2 Topotecan Hydrochloride;Veliparib
26 A Phase II Evaluation Of OSI-774 (NSC #718781) In The Treatment Of Persistent or Recurrent Squamous Cell Carcinoma Of The Cervix Completed NCT00031993 Phase 2 erlotinib hydrochloride
27 Safety and Efficacy of Gemcitabine Based Neoadjuvant Chemotherapy Followed by Chemoradiation in Locally Advanced Cervical Cancer Patients and Association With Human Equilibrative Nucleoside Transporter 1 (hENT1) Expression Completed NCT02309658 Phase 2 gemcitabine;cisplatin
28 Phase I/II Study of Niraparib With Radiotherapy for Treatment of Metastatic Invasive Carcinoma of the Cervix Recruiting NCT03644342 Phase 1, Phase 2 Nirapaib
29 A Phase II Clinical Trial to Evaluate the Potential of Concomitant Chemoradiotherapy With Gemcitabine in Patients With Locally Advanced Carcinoma of Cervix and Renal Disease Recruiting NCT03101995 Phase 2 Gemcitabine
30 A Phase II Evaluation of ADXS11-001 (NSC 752718) in the Treatment of Persistent or Recurrent Squamous or Non-Squamous Cell Carcinoma of the Cervix Active, not recruiting NCT01266460 Phase 2
31 Randomized Phase II Study of Zoledronic Acid vs Observation on Bone Mineral Density and Incidence of Micrometastasis in Women Undergoing Pelvic Radiation for Cervical Cancer Terminated NCT00966992 Phase 2 Zoledronic acid
32 A Limited Access Phase I Trial of Paclitaxel, Cisplatin and CTEP Supplied Agent ABT-888 (Veliparib) (NSC#737664) in the Treatment of Advanced, Persistent, or Recurrent Carcinoma of the Cervix Completed NCT01281852 Phase 1 Cisplatin;Paclitaxel;Veliparib
33 A Phase Ib Study Evaluating BGJ398 in Combination With Chemotherapeutic Regimen in Patients With Stage IV, Recurrent or Persistent Carcinoma of The Cervix and Other Solid Tumors Withdrawn NCT02312804 Phase 1 BGJ398;Carboplatin;Paclitaxel
34 Prospective, Randomized and Multicentre Study for Investigation of Valence of Sentinel Lymph Nodes Concept in Patients With Cervical Cancer ≤ 2 cm Unknown status NCT01157962
35 Prospective, Randomised and Multi-centric Therapy Optimisation Study for Examining the Influence of Surgical Staging on the Oncological Results for Patients With Cervix Carcinoma of the FIGO Stages IIB-IV After Chemoradiation Unknown status NCT01049100
36 Evaluation of the Diagnostic Performance of HPV E6/E7 mRNA Versus Oncogenic HPV DNA as a Secondary Triage Test for VIA Positive Women in Cervical Cancer Screening Program Unknown status NCT02116920
37 The Correlation Between the Haplotype of Human Leukocyte Antigen (HLA) and Human Papillomavirus Unknown status NCT00154479
38 Economic Evaluation of Three Populational Screening Strategies for Cervical Cancer in the County of Valles Occidental: CRICERVA Clinical Trial. Unknown status NCT01373723
39 A Pilot Study to Assess the Suitability of DCE-MRI for Detection of Vascular Changes After Vaginal Brachytherapy Completed NCT01991808
40 Predicting Outcome in Cervix Carcinoma: a Prospective Study Completed NCT01825005
41 Cisplatin Plus One Day 24 Hour Infusion of High-Dose 5-Fluorouracil for Stage IVB, Recurrent or Metastatic Carcinoma of the Uterine Cervix. Completed NCT02207660 Cisplatin,P-HDFL
42 Vaginal Length, Elasticity, Lubrication And Sexual Function In Women With Stage IB2 Cervix Carcinoma Completed NCT00053261
43 Squamous Cell Carcinoma Antigen as a Marker of Sinonasal Inverted Papilloma Completed NCT01827423
44 Pilot Study of Magnetic Resonance Imaging Guided Brachytherapy Completed NCT00112307
45 Prospective Study on the Sparing of Organs at Risk in High Dose Rate Brachytherapy for Cervix Cancer Completed NCT01681342
46 Assessment of Perioperative Morbidity in Gyneco-oncology According to the Surgical Approach : Coelioscopy Versus Robot-assisted Coelioscopy Completed NCT01247779
47 A Phase II Randomized Trial Comparing Intensity Modulated Radiation Therapy (IMRT) With Conventional Radiation Therapy in Stage IIB Carcinoma Cervix Completed NCT00193804
48 Concomitant Chemo-radiation in Advanced Stage Carcinoma Cervix: A Phase III Randomized Trial Completed NCT00193791
49 To Assess the Feasibility and Impact of Computed Tomotherapy (CT) and Magnetic Resonance Imaging (MRI) Fusion on Radiation Treatment Planning for Ten Patients With Cancer of the Cervix Completed NCT00126841
50 Comparison of Tomotherapy Versus Intensity-modulated Step-and-shoot and Conventional Radiation Treatment Plans for Patients With Locally-advanced Squamous Cell Carcinoma of the Cervix Completed NCT00124488

Search NIH Clinical Center for Cervix Carcinoma

Genetic Tests for Cervix Carcinoma

Genetic tests related to Cervix Carcinoma:

# Genetic test Affiliating Genes
1 Carcinoma of Cervix 29 FGFR3

Anatomical Context for Cervix Carcinoma

The Foundational Model of Anatomy Ontology organs/tissues related to Cervix Carcinoma:

Cervix Uteri, Cervical Area

MalaCards organs/tissues related to Cervix Carcinoma:

Cervix, Lymph Node, Breast, Bone, Testes, Uterus, Endothelial

Publications for Cervix Carcinoma

Articles related to Cervix Carcinoma:

(show top 50) (show all 1687)
# Title Authors PMID Year
Extrahepatic Malignancies After Treatment with Direct Antiviral Agents for Chronic HCV Infection. 61
31407252 2020
Human papilloma virus-associated metachronous squamous cell carcinoma of the larynx and uterine cervix: Case report and review of the literature. 61
32300633 2020
Development of oxathiino[6,5-b]pyridine 2,2-dioxide derivatives as selective inhibitors of tumor-related carbonic anhydrases IX and XII. 61
32460112 2020
A new class of dimeric product isolated from the fungus Chaetomium globosum: evaluation of chemical structure and biological activity. 61
32024969 2020
Antiviral, Antibacterial, Antifungal, and Cytotoxic Silver(I) BioMOF Assembled from 1,3,5-Triaza-7-Phoshaadamantane and Pyromellitic Acid. 61
32369972 2020
New cyclopeptide alkaloids from the whole plant of Justicia procumbens L. 61
32347116 2020
Isoshamixanthone: a new pyrano xanthone from endophytic Aspergillus sp. ASCLA and absolute configuration of epiisoshamixanthone. 61
30663363 2020
Synthesis of novel feruloyl dipeptides with proapoptotic potential against different cancer cell lines. 61
32120076 2020
Terretonin O: a new meroterpenoid from Aspergillus terreus. 61
30602325 2020
Phase 1/2 study of concurrent chemoradiotherapy with weekly irinotecan hydrochloride for advanced/recurrence uterine cancer: A multi-institutional study of Kansai Clinical Oncology Group. 61
32410799 2020
Meleagrin from marine fungus Emericella dentata Nq45: crystal structure and diverse biological activity studies. 61
32189530 2020
Evaluation of the cytotoxic and genotoxic effects of mycotoxin fusaric acid. 61
30204001 2020
Cervix neuroendocrine carcinoma presenting with severe hypokalemia and Cushing's syndrome. 61
31970585 2020
Dermatomyositis presenting as heart failure revealed a concealed cervical malignancy: an infrequent clinical nexus. 61
32111708 2020
Intracardiac metastasis from unknown uterine cervical cancer with severe thrombocytopenia. 61
31765009 2020
Synthesis, Structural, and Cytotoxic Properties of New Water-Soluble Copper(II) Complexes based on 2,9-Dimethyl-1,10-Phenanthroline and Their One Derivative Containing 1,3,5-Triaza-7-Phosphaadamantane-7-Oxide. 61
32046362 2020
A novel peptide-based electrochemical biosensor for the determination of a metastasis-linked protease in pancreatic cancer cells. 61
31989193 2020
Design, Synthesis, and Biological Evaluation of Novel C5-Modified Pyrimidine Ribofuranonucleosides as Potential Antitumor or/and Antiviral Agents. 61
30799795 2020
Structurally diverse metabolites from the rare actinobacterium Saccharothrix xinjiangensis. 61
31451754 2020
Synthesis and cytotoxic activities of novel copper and silver complexes of 1,3-diaryltriazene-substituted sulfonamides. 61
30362387 2019
Impact of diabetes on gastrointestinal and urinary toxicity after radiotherapy for gynecologic malignancy. 61
32231858 2019
Evaluation of Volumetric Doses of Organs at Risk in Carcinoma Cervix Patients with HDR Intracavitary Brachytherapy and Comparison of CT-based and Conventional Plans. 61
32039090 2019
Comparative Study of Neoadjuvant Chemotherapy Followed by Definitive Chemoradiotherapy Versus Definitive Chemoradiotherapy Alone in Locally Advanced Carcinoma of Cervix. 61
31844371 2019
On the potential use of dynamic contrast-enhanced (DCE) MRI parameters as radiomic features of cervical cancer. 61
31523829 2019
Pentafluorophenyl Platinum(II) Complexes of PTA and its N-Allyl and N-Benzyl Derivatives: Synthesis, Characterization and Biological Activity. 61
31779206 2019
Formulation of normal tissue irradiation volumes in Co-60 and Ir-192 HDR ICBT of Ca cervix using Total Reference Air Kerma (TRAK). 61
31660050 2019
Overcoming radioresistance in WiDr cells with heavy ion irradiation and radiosensitization by 2-deoxyglucose with photon irradiation. 61
31517070 2019
Graphene oxide size and structure pro-oxidant and antioxidant activity and photoinduced cytotoxicity relation on three cancer cell lines. 61
31648133 2019
Skin metastasis from squamous cell carcinoma of the cervix to the lower extremities: Case report and review of the literature. 61
31742189 2019
Nodal metastasis of cervix carcinoma- As a probable cause of bone erosion. 61
31898657 2019
Corrigendum to "Tanshinone IIA inhibits cervix carcinoma stem cells migration and invasion via inhibiting YAP transcriptional activity" [Biomed. Pharmacother. 105 (2018) 758-765]. 61
31227337 2019
Coumamarin: a first coumarinyl calcium complex isolated from nature. 61
31289369 2019
First-in-human phase I study of the microtubule inhibitor plocabulin in patients with advanced solid tumors. 61
30411218 2019
Synthesis of diglycosylated (di)sulfides and comparative evaluation of their antiproliferative effect against tumor cell lines: A focus on the nature of sugar-recognizing mediators involved. 61
31302458 2019
Light-stable polypyridine silver(i) complexes of 1,3,5-triaza-7-phosphaadamantane (PTA) and 1,3,5-triaza-7-phosphaadamantane-7-sulfide (PTA[double bond, length as m-dash]S): significant antiproliferative activity of representative examples in aqueous media. 61
31237306 2019
Design, synthesis and anticervical cancer activity of new benzofuran-pyrazol-hydrazono- thiazolidin-4-one hybrids as potential EGFR inhibitors and apoptosis inducing agents. 61
31200286 2019
Oxidative stress mediated by gyrophoric acid from the lichen Umbilicaria hirsuta affected apoptosis and stress/survival pathways in HeLa cells. 61
31426865 2019
Genetic polymorphisms in DNA repair genes and their association with cervical cancer. 61
30870085 2019
Synthesis, X-ray structure, physicochemical properties and anticancer activity of mer and fac Ru(iii) triphenylphosphine complexes with a benzothiazole derivative as a co-ligand. 61
31241117 2019
Combination Chemotherapy of L1210 Tumors in Mice with Pretubulysin and Methotrexate Lipo-Oligomer Nanoparticles. 61
31025870 2019
Combination of SB431542, CHIR99021 and PD0325901 has a synergic effect on abrogating valproic acid‑induced epithelial‑mesenchymal transition and stemness in HeLa, 5637 and SCC‑15 cells. 61
30942451 2019
The Incidence and Clinical Significance of Atypical Glandular Cells of Undetermined Significance on Cervical Pap Smears. 61
31242982 2019
Treatment of cervix carcinoma FIGO IIIb with Photofrin II as a radiosensitizer: a case report. 61
30892313 2019
Extracts from Cell Suspension Cultures of Strawberry (Fragaria x ananassa Duch): Cytotoxic Effects on Human Cancer Cells. 61
31060218 2019
Diverse polyketides and alkaloids from Penicillium sp. KHMM: structural elucidation, biological and molecular docking studies. 61
30645191 2019
Parvifoline Derivatives as Tubulin Polymerization Inhibitors. 61
30883116 2019
Synthesis of New Derivatives of Benzofuran as Potential Anticancer Agents. 61
31003438 2019
Cytotoxic, antimicrobial and antiviral secondary metabolites produced by the plant pathogenic fungus Cytospora sp. CCTU A309. 61
30807789 2019
Reductively cleavable polymer-drug conjugates based on dendritic polyglycerol sulfate and monomethyl auristatin E as anticancer drugs. 61
30794827 2019
[Composition and mode of action of adjuvants in licensed viral vaccines]. 61
30830257 2019

Variations for Cervix Carcinoma

ClinVar genetic disease variations for Cervix Carcinoma:

6 ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 FGFR3 NM_001163213.1(FGFR3):c.742C>T (p.Arg248Cys)SNV Pathogenic 16332 rs121913482 4:1803564-1803564 4:1801837-1801837
2 FGFR3 NM_001163213.1(FGFR3):c.1626C>G (p.Asn542Lys)SNV Pathogenic 16338 rs28933068 4:1807371-1807371 4:1805644-1805644
3 FGFR3 NM_001163213.1(FGFR3):c.746C>G (p.Ser249Cys)SNV Pathogenic 16339 rs121913483 4:1803568-1803568 4:1801841-1801841
4 FGFR3 NM_001163213.1(FGFR3):c.1955A>C (p.Lys652Thr)SNV Pathogenic 65855 rs121913105 4:1807890-1807890 4:1806163-1806163
5 FGFR3 NM_001163213.1(FGFR3):c.749C>G (p.Pro250Arg)SNV Pathogenic/Likely pathogenic 16340 rs4647924 4:1803571-1803571 4:1801844-1801844
6 TP53 NM_001126112.2(TP53):c.747G>T (p.Arg249Ser)SNV Conflicting interpretations of pathogenicity 12352 rs28934571 17:7577534-7577534 17:7674216-7674216
7 FGFR3 NM_001163213.1(FGFR3):c.1144G>A (p.Gly382Arg)SNV Conflicting interpretations of pathogenicity 16327 rs28931614 4:1806119-1806119 4:1804392-1804392
8 FGFR3 NM_001163213.1(FGFR3):c.1999G>T (p.Ala667Ser)SNV Uncertain significance 465350 rs764892330 4:1808017-1808017 4:1806290-1806290
9 FGFR3 NM_001163213.1(FGFR3):c.2159A>G (p.Asn720Ser)SNV Uncertain significance 521225 rs139773438 4:1808395-1808395 4:1806668-1806668
10 FGFR3 NM_001163213.1(FGFR3):c.200G>A (p.Gly67Asp)SNV Uncertain significance 546226 rs369232922 4:1801071-1801071 4:1799344-1799344

Expression for Cervix Carcinoma

Search GEO for disease gene expression data for Cervix Carcinoma.

Pathways for Cervix Carcinoma

GO Terms for Cervix Carcinoma

Biological processes related to Cervix Carcinoma according to GeneCards Suite gene sharing:

(show all 11)
# Name GO ID Score Top Affiliating Genes
1 gene silencing by miRNA GO:0035195 9.89 MIR362 MIR218-1 MIR200A MIR199A1 MIR141
2 negative regulation of cell death GO:0060548 9.58 STAT3 RHOA BECN1
3 cellular response to amyloid-beta GO:1904646 9.5 MIR200A FOXO3 ABCC1
4 DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator GO:0006978 9.48 TP53 FOXM1
5 regulation of neural precursor cell proliferation GO:2000177 9.46 RHOA FOXO3
6 transepithelial transport GO:0070633 9.43 ABCC1 ABCB1
7 cellular response to glucose starvation GO:0042149 9.43 TP53 FOXO3 BECN1
8 export across plasma membrane GO:0140115 9.37 ABCC1 ABCB1
9 positive regulation of pri-miRNA transcription by RNA polymerase II GO:1902895 9.33 TP53 STAT3 FOXO3
10 positive regulation of neuron apoptotic process GO:0043525 9.26 TP53 RHOA MIR200A FOXO3
11 response to drug GO:0042493 9.1 TP53 STAT3 RHOA FOXO3 ABCC1 ABCB1

Molecular functions related to Cervix Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 ubiquitin protein ligase binding GO:0031625 9.71 TP53 FHIT BECN1 ABCB1
2 protein phosphatase binding GO:0019903 9.5 TP53 STAT3 CDC27
3 xenobiotic transmembrane transporter activity GO:0042910 9.37 ABCC1 ABCB1
4 mRNA binding involved in posttranscriptional gene silencing GO:1903231 9.35 MIR362 MIR218-1 MIR200A MIR199A1 MIR141
5 efflux transmembrane transporter activity GO:0015562 9.26 ABCC1 ABCB1
6 protein kinase binding GO:0019901 9.17 TP53 STAT3 RHOA FOXO3 FOXM1 DUSP3
7 xenobiotic transmembrane transporting ATPase activity GO:0008559 9.16 ABCC1 ABCB1

Sources for Cervix Carcinoma

9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
31 HPO
32 ICD10
33 ICD10 via Orphanet
37 LifeMap
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
54 Novoseek
57 OMIM via Orphanet
61 PubMed
70 Tocris
72 UMLS via Orphanet
Loading form....